GLP-1 Tracker: GLP-1 Demand Holds Firm During July 4 Holiday Week (W/E July 3rd)

Research evidence excerpt

GLP-1 Tracker: GLP-1 Demand Holds Firm During July 4 Holiday Week (W/E July 3rd)

10 July 2026

US Biopharmaceuticals

GLP-1 Tracker: GLP-1 Demand Holds Firm During July 4 Holiday

Week (W/E July 3rd)

Although holidays are typically associated with script volatility, GLP-1 volumes surprisingly Courtney Breen

+1 917 344 8407 bucked the typical seasonal July 4th downturn this week, with total scripts up +2.3% WoW,

courtney.breen@bernsteinsg.com or +59k. It is too early to determine whether strength was driven by the July 1 Bridge

program, pre-holiday stock-up, or timing noise; next week’s channel-specific data should

Woody Polglase provide more clarity. Foundayo TRx declined sequentially week-over-week, while Wegovy

+1 917 344 8314

woody.polglase@bernsteinsg.com Pill increased; specifically, Foundayo saw 19,549 TRx in week 13, -282 WoW and -1.4%

sequentially. Wegovy Pill saw 153k TRx this week, up +3.6k sequentially, or ~+2.4%. Given

Louisa Qiu that our last tracker update was on Monday, this update does not include incremental NBRx

+1 917 344 8495 data.

louisa.qiu@bernsteinsg.com

Per LLY IR, IQVIA capture rates for the Foundayo weekly data have improved, and stood at

Specialist Sales ~90% in Q2; the equivalent rate for Zepbound is >90%. As a reminder - direct-to-consumer

Christian Moore advertising for Foundayo is still in its early innings, and we expect to see script inflection as

+1 917 344 8555 customer/patient awareness increases over the months once full-blown advertising is in play.

christian.moore@bernsteinsg.com

Finally, reimbursement of GLP-1s for obesity in Medicare began last week (1st Jul) through

the GLP-1 Bridge program. We will be monitoring channel-level scripts (TRx/NBRx) in the

coming weeks to assess the impact.